ECA Flags Abuse Of Dominance In Pharma Distribution

On 5 November 2025, the Egyptian Competition Authority (ECA) issued their findings that a leading distributor of Cetrotide, a scarce and medically essential IVF medication, abused its dominant market position, signaling scrutiny for distributors of critical or limited-supply medicines. The case highlights risks for companies controlling exclusive imports or distribution of essential products and the potential consequences of restricting supply, discriminating among customers, or enabling resale at inflated prices.

In their investigation the ECA worked in coordination with the Egyptian Drug Authority (EDA) to refine its investigative tools and strengthen market oversight. The cooperation contributed to uncovering anti-competitive practices in this market.